HUTCHMED (China) Limited (HCM)
Similar size · 1.13x market cap
Drug Manufacturers - Specialty & Generic
YouTube · Q1 2026 · 2026-06-05
ALVO · NasdaqGM
Alvotech
Drug Manufacturers - Specialty & Generic · Luxembourg
USD 5.879.9% daily changeQuote 2026-09-18 · USD
- Market cap (USD)
- US$2.09B
- Trailing P/E
- —
- Forward P/E
- 25.71x
- Quarterly revenue growth
- -38.9%
- Trailing net margin
- -36.3%
- Indicated dividend yield
- —
Snapshot 2026-09-20 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-11-11 (provider estimate, not issuer-confirmed).
Company background
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Company websiteH1 2026
Go beyond the headline.
Alvotech (ALVO) H1 2026: Revenue -30.8%, Guidance Unchanged, And A 2x Second Half
Published 2026-08-23
Comparable businesses
ALVO peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | ALVOAlvotechSnapshot 2026-09-20Financial period: 2026-06-30 | HCMHUTCHMED (China) LimitedSnapshot 2026-09-20Financial period: 2026-06-30 | PAHCPhibro Animal Health CorporationSnapshot 2026-09-20Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$2.09B | US$2.38B | US$1.40B | US$1.89Bn=2 |
| Forward P/EProvider forward earnings estimate | 25.71x | 52.40x | 8.98x | 30.69xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 44.94x | — | 8.66x | — |
| Revenue growthLatest quarter vs prior-year quarter | -38.9% | 0.2% | 4.8% | 2.5%n=2 |
| Operating marginLatest reported quarter | -11.1% | 0.3% | 10.6% | 5.5%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | -5.9% | -0.8% | -1.4% | -1.1%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | 17.28x | — | 2.91x | — |
| Debt / equityTotal debt / positive book equity | — | 0.07x | 2.06x | 1.07xn=2 |
| Trailing P/ETrailing twelve-month earnings | — | 136.70x | 14.22x | 75.46xn=2 |
| Price / bookPrice / positive book equity per share | — | 1.88x | 3.64x | 2.76xn=2 |
| EV / salesEnterprise value / trailing revenue | 6.88x | 2.02x | 1.39x | 1.71xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | — | -96.5% | 24.6% | -36.0%n=2 |
| Gross marginTrailing twelve months | 60.7% | 13.3% | 33.3% | 23.3%n=2 |
| Net marginTrailing twelve months | -36.3% | 3.3% | 6.6% | 4.9%n=2 |
| Return on equityProvider trailing return; positive equity only | — | 1.5% | 29.7% | 15.6%n=2 |
| Free cash flow marginTrailing free cash flow / revenue | -24.9% | -3.4% | -1.3% | -2.4%n=2 |
| Dividend yieldIndicated annual dividend / price | — | — | 1.4% | — |
| Earnings payoutProvider trailing dividend payout | 0.0% | 0.0% | 19.8% | 9.9%n=2 |
| Current ratioCurrent assets / current liabilities | 1.65x | 5.64x | 2.96x | 4.30xn=2 |
| BetaProvider historical market sensitivity | 0.22 | 0.45 | 0.47 | 0.46n=2 |
YouTube · Q1 2026 · 2026-06-05
Phibro Animal Health Corporation (PAHC)
Similar size · 0.67x market cap
Drug Manufacturers - Specialty & Generic
YouTube · Q4 FY2026 · 2026-08-28
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for ALVO
H1 20262026-08-23
Alvotech (ALVO) H1 2026: Revenue -30.8%, Guidance Unchanged, And A 2x Second Half
Presentation · 2026-08-23 · YouTube